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Abstract 
Purpose: To investigate the efficacy of capecitabine and ludartin in the treatment of colon cancer in 
mice.  
Methods: Mice model of colon cancer was used in this study. Quantitative real-time polymerase chain 
reaction (Qrt-PCR) was used to quantify the expression of vascular endothelial growth factor (VEGF) 
mRNA. Micro-vessel density was assessed using immunohistochemical analysis. 
Results: When administered separately, capecitabine and ludartin treatments significantly suppressed 
tumor growth in the mice model of colon cancer for 4 weeks, compared to control group. Co-
administration of capecitabine and ludartin significantly inhibited tumor growth for 6 weeks (p < 0.05). 
Symptoms of colon cancer such as weight loss, skin discoloration and leukopenia were observed in 
untreated control group. However, these symptoms were completely absent in the group treated with 
combination of capecitabine and ludartin. The combined treatment also prevented colon cancer-induced 
increase in white blood cell (WBC) count, and increased median survival time of colon cancer mice from 
38 to 55 days. Expression of VEGF in combination (capecitabine + ludartin) treatment group was 
significantly lower than in the control, i.e., untreated group (p ˂ 0.05). The combination treatment group 
also had significantly lower micro-vessel density in the tumor tissues, compared to the untreated control 
mice (p < 0.05). 
Conclusion: These results show that a combination treatment of capecitabine and ludartin effectively 
inhibits colon tumor growth and angiogenesis in mice via a mechanism involving suppression of VEGF 
expression. Thus, capecitabine and ludartin combination is a potentially suitable treatment for colon 
cancer.  
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Colon cancer, one of the common malignant 
tumors of the digestive tract, occurs at the 
junction between the rectum and the sigmoid 
colon [1,2]. It is more common in males than in 
females and affects mostly people in the age 
group of 50-60 year [1,2]. Studies have revealed 
that colon cancer progression involves several 
mechanisms such as alteration of the apoptotic 
pathway and mutation of cell cycle components 
[3-6]. It has also been observed that activation of 
infiltrating immune cells and immunosuppressive 
pathways play vital role in the development and 
progression of colon cancer [7]. Treatment 
strategies for colon cancer include 
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chemotherapy, radiotherapy and surgical 
intervention [7]. 
 
Ludartin is a sesquiterpene lactone with 
cytotoxic, antitumor and anti-bactericidal 
properties [8].  Synthetic analogs of ludartin have 
also shown promising pharmaceutical activities 
[9]. In view of the antitumor properties of ludartin, 
the present study was designed to investigate its 
effect on colon tumor growth in s mice model. 
Selective delivery of 5-fluorouracil into tumor 
cells is achieved by the use of capecitabine [10]. 
Capecitabine, used alone or in combination with 
other drugs has been investigated for the 
treatment of gastric cancers [10]. High doses of 
capecitabine cause result in some unwanted side 
effects such as drug resistance, diarrhoea and 
lymphopenia, but at lower doses, the drug is 
effective for cancer treatment [10].  
 
The present study investigates the effect of 
combined treatment with ludartinin and 
capecitabine on colon tumor growth in a mice 






Twenty five female nude BALB/c mice, aged 7 - 
8 weeks, were supplied by the Animal 
Experiment Centre of Beijing, China. The mice 
were housed under conditions free from 
pathogens at room temperature, 55 % humidity 
and circadian 12 h light/12 h dark rhythm. All the 
animals were allowed free access to CLEA 
rodent diet (CA-1) and tap water. 
 
Chemicals and cell culture 
 
Ludartin amd azoxymethane (AOM) were 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Capecitabine was supplied by Roche 
Pharmaceutical Company (Nutley, NJ, USA). 
Dextran sulfate sodium (DSS; cat. no. 160110) 
was product of MP Biomedicals, LLC (Aurora, 
OH). HCT-116 cancer cell line was obtained from 
Cell Resource Centre for Biomedical Research, 
Aging and Cancer, Tohoku University, Japan. 
The cells were cultured in RPMI-1640 medium at 
37 oC under an atmosphere of 5 % CO2 and 95 
% air. The medium was supplemented with 10 % 
NBS containing penicillin (100 U/mL) and 
streptomycin (100 µg/mL). 
 
Animal experiment design 
 
The experimental procedures used in the animal 
studies were performed in accordance with the 
international Guide for the Care and Use of 
Laboratory Animals [11]. Approval for the study 
was obtained from the Ethics Committee of 
Hebei United University for the use of animals. 
Colon cancer was induced in mice by 
administration of AOM and DSS. The mice were 
divided into five groups of 5 animals each. Four 
groups received AOM and DSS intraperitoneally 
and the normal control was given saline only. 
The AOM was given through intraperitoneal 
injection at a dose of 10 mg/kg body weight. An 
aqueous solution of DSS [(1.5 g of DSS was 
dissolved in 100 mL of water to get 1.5 % (w/v)] 
was given to the mice orally one week after AOM 
injection. Mice in the capecitabine, ludartin and 
combination treatment groups were administered 
200 mg/kg capecitabine, 10 µM ludartin, and 100 
mg/kg capeitabine plus 10 µM ludartin, 
respectively daily by gavage for one month. At 
the end of the treatments, the mice were 
sacrificed under 10 % chloral hydrate (3 mg/kg) 
anaesthesia administered intraperitoneally. 
 
Analysis of tumor growth and side effects 
 
During the study, mice in all groups were 
weighed and examined carefully to record 
changes in body weight and physical 
appearance. Blood samples were collected for 
determination of white blood cell (WBC) count. 
 
Real-time polymerase chain reaction (RT-
PCR) analysis 
 
After the mice were sacrificed, the colon tumour 
was excised and stored under liquid nitrogen till 
further analysis. Total RNA was extracted from 
the colon tumor tissue using TRIzol reagent 
(Invitrogen, USA). Reverse transcription of the 
extracted RNA was performed using oligo (dT) 
primers. Analysis of the mRNA expression was 
carried out by quantitative real time reverse 
transcription-PCR. The primers used for reverse 
transcription of VEGF were 5'-GAGCCTTGCC 
TTGCTGCTCTAC for forward and 5'-
CACCAGGGTCTCGATTGGATG for backward. 
For β-actin, the primers were 5'-TGGCACC  
CAGCACAATGAA (forward) and 5'-CTAAGT 
CATAGTCCGCCTAGAAGCA (backward). 
Amplification of the cDNAs was done over 45 
cycles using PCR Thermal Cycler (Takara Bio) 
and SYBR Green. The amplification involved a 
two-step procedure consisting of 5 sec at 95 oC 
and 30 sec at 60 oC. 
 
Analysis of VEGF and CD31 in colon cancer 
tissues 
 
Colon tumor tissues were fixed in 10 % buffered 
formalin phosphate. The fixed tissues were 
embedded in paraffin and subsequently sliced 
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into thin sections for immunohistochemical 
examination using PV-9000 kit (Beijing 
Zhongshan Goldenbridge Biotechnology 
Company, Beijing, China). The tissue sections 
were de-waxed in boiling xylene and then treated 
with VEGF rabbit anti-human monoclonal 
antibody (Fuzhou Maixin Company, China), and 
CD31 rat anti-mouse monoclonal antibody 
(Dako, Japan) at 1 : 100 dilution. The treatment 
was performed for 3 minutes under pressure in 
citrate buffer (pH 6.0). Expression of VEGF was 
indicated by presence of stained cytoplasm 
VEGF [12]. 
 
Determination of micro-vessel density 
 
Micro-vessel density was determined 
immunohistochemically [13], using antibodies 
against endothelial marker CD31. Initially, the 
sections were examined at a magnification of x 
40 and x 100, to localize regions of high 
neovascularization. Endothelial cells that stained 
yellow-brown were taken as micro-vessel. The 
selected microvessels were further examined at 
a high magnification (x 200) to determine the 
micro-vessel density (MVD) count, and the 
images were captured with Zeiss fluorescence 
microscope (Zeiss Inc.) equipped with an 




Results are presented as mean ± S.E.M. 
Analysis of data on survival was performed using 
Kaplan Meier analysis. ANOVA and Student-
Newman-Keuls tests were also used for data 
analysis. SPSS 17.0 software package was used 
for all statistical analyses. Values of p < 0.05 




Effect of capecitabine and ludartin on tumour 
growth 
 
In the control group, tumour growth was prompt 
and after 6 weeks, all mice had large tumour 
sizes (Figure 1). Tumour growth was delayed 
markedly in the capecitabine-treated group of 
mice for 4 weeks (p < 0.02; Figure 1). Treatment 
with ludartin exhibited tumor growth-delaying 
effect similar to that of capecitabine. Combination 
of capecitabine and ludartin brought about 
significant inhibition of tumour growth, so much 
so that there was no tumour growth was 




Figure 1: Tumour growth in mice treated with 
capecitabine, ludartin, and combination of 
capecitabine and ludartin. *p < 0.05 and **p < 0.02 of 
control verses normal (◊ Normal, ▪ Untreated, ○ 
Ludartin □ Capecitabine, ● Combination treatment) 
 
Effect of capecitabine and ludartin on WBC 
count 
 
Mice in the control, untreated group showed 
various symptoms such as weight reduction, skin 
discoloration and leukopenia during the 6-week 
study. However, no such symptoms were 
observed in the mice treated with capecitabine, 
ludartin or combination of capecitabine and 
ludartin. After two weeks of tumour 
establishment, WBC count was same in all the 
groups of mice. No significant changes in WBC 
count were seen in the capecitabine, ludartin or 
combination (capecitabine and ludartin) 
treatment groups. On the other hand, there were 
significant decreases in WBC count in the control 
group within two weeks (p < 0.05; Figure 2). 
 
 
Figure 2: Effect of AOM/DSS and treatment on WBC 
count of mice. *p < 0.05 and **p < 0.05 of untreated 
control verses normal. (◊ Normal, ▪ Untreated, ○ 
Ludartin □ Capecitabine, ● Combination treatment) 
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Effect of capecitabine and ludartin on mice 
survival 
 
Mice in the control group had median survival 
time of 38 days. The median survival times of 
mice in capecitabine and ludartin treatment 
groups were 49 and 50 days, respectively (p < 
0.02). The median survival time of mice in the 
combination treatment group was 55 days (p < 
0.02). 
 
Effect of capecitabine and ludartin on VEGF 
expression 
 
The expression of VEGF gene was significantly 
higher in the untreated control mice group, when 
compared to normal healthy mice (Figure 3). 
However, VEGF expression was significantly 
lower in the capecitabine and ludartin treatment 
groups, relative to the control group. Expression 
of VEGF in the combination (capecitabine and 
ludartin) treatment group was significantly lower 
when compared to the capecitabine and ludartin 




Figure 3: Effect of capecitabine, ludartin and 
combination of capecitabine plus ludartin on VEGF 
expression in the colon of mice with colon tumour 
 
Effect of capecitabine and ludartin on colon 
tissue histopathology of mice 
 
Histopathological examination of tissues from the 
mice of control group showed markedly higher 
count of microvessels, when compared to the 
normal mice (Figure 4). Microvessel count was 
lower in the capecitabine and ludartin treatment 
groups of mice, relative to the control group. 
Combination treatment produced even lower 
micro-vessel counts in the colon tumour tissues, 
when compared to the capecitabine or ludartin 




Investigation of the effect of capecitabine and 
ludartin on colon tumour growth either alone or in 
combination revealed that combination of 
capecitabine and ludartin was an effective 
treatment regimen. The combination of 
capecitabine and ludartin inhibited colon tumor 
growth and angiogenesis. Therapeutic strategies 
using known drugs in combination with 
phytochemicals have been found effective for 
treatment of various disorders, and are highly 
encouraged [14,15]. In the present study, the 
effect of capecitabine and ludartin separately or 
in combination on colon tumor angiogenesis in a 
mice model was investigated. The results 
showed that tumor growth in control mice was 
prompt, resulting in large tumour size in all the 
animals within one month. 
 
However, capecitabine treatment caused marked 
delay in tumour growth for 21 days. Ludartin 
treatment also exhibited tumour growth-inhibiting. 
However the most effective inhibition of tumour 
growth was produced by the combination of two 
drugs, which resulted in absence of tumor growth 
for one month. At lower doses, capecitabine is 
efficient for cancer treatment because of its 
specificity for tumour cells [10]. Mice in the 




Figure 4: Effect of capecitabine, ludartin and the combination treatment on AOM/DSS-mediated increase in 
colon micro-vessel density in colon cancer model mice. (x 200) 
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as weight reduction, skin discoloration and 
leukopenia, all of which were reversed by 
capecitabine, ludartin or combination 
(capecitabine and ludartin) treatment. 
 
VEGF plays an important role in the progression 
of tumour angiogenesis; its expression is a 
characteristic of angiogenesis [16,17]. Studies 
have shown that higher expression of VEGF in 
tumor cells is associated with the development of 
drug resistance [18-20]. The present study 
showed that in the colon tumor cells of control, 
untreated group, the expression of VEGF gene 
was markedly higher than that in normal, healthy 
control mice. However, the expression of VEGF 
in the colon tumor-bearing mice was markedly 
reduced on treatment with combination of 
capecitabine and ludartin. Higher micro-vessel 
density in tumour cells is considered to be the 
characteristic feature of angiogenesis [21]. The 
expression of VEGF and micro-vessel count are 
directly related [22]. In the present study, results 
from histopathological examination of tumour 
tissues of the untreated, control mice showed 
markedly higher count of micro-vessels than 
corresponding values for healthy control mice. 
Treatment with combination of capecitabine and 
ludartin led to a significant decrease in the count 
of micro-vessels in the tumour tissues, relative to 





The findings of this study show that the 
combination of capecitabine and ludartin inhibits 
colon tumour growth and angiogenesis in mice 
via suppression of VEGF expression. Thus, 
capecitabine and ludartin combination has a 
potential for development into a suitable 
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